125 related articles for article (PubMed ID: 7585503)
1. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine.
Pan ZK; Ikonomidis G; Pardoll D; Paterson Y
Cancer Res; 1995 Nov; 55(21):4776-9. PubMed ID: 7585503
[TBL] [Abstract][Full Text] [Related]
2. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine.
Pan ZK; Weiskirch LM; Paterson Y
Cancer Res; 1999 Oct; 59(20):5264-9. PubMed ID: 10537307
[TBL] [Abstract][Full Text] [Related]
3. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.
Sewell DA; Douven D; Pan ZK; Rodriguez A; Paterson Y
Arch Otolaryngol Head Neck Surg; 2004 Jan; 130(1):92-7. PubMed ID: 14732776
[TBL] [Abstract][Full Text] [Related]
4. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
[TBL] [Abstract][Full Text] [Related]
5. Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens.
Mata M; Paterson Y
J Immunol; 1999 Aug; 163(3):1449-56. PubMed ID: 10415046
[TBL] [Abstract][Full Text] [Related]
6. The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine comprises multiple effector mechanisms.
Weiskirch LM; Pan ZK; Paterson Y
Clin Immunol; 2001 Mar; 98(3):346-57. PubMed ID: 11237558
[TBL] [Abstract][Full Text] [Related]
7. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
8. The defined attenuated Listeria monocytogenes delta mp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma.
Paglia P; Arioli I; Frahm N; Chakraborty T; Colombo MP; Guzmàn CA
Eur J Immunol; 1997 Jun; 27(6):1570-5. PubMed ID: 9209512
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity.
Mendiratta SK; Quezada A; Matar M; Wang J; Hebel HL; Long S; Nordstrom JL; Pericle F
Gene Ther; 1999 May; 6(5):833-9. PubMed ID: 10505108
[TBL] [Abstract][Full Text] [Related]
10. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
McLaughlin JP; Schlom J; Kantor JA; Greiner JW
Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
[TBL] [Abstract][Full Text] [Related]
11. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
12. Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine.
Schafer R; Portnoy DA; Brassell SA; Paterson Y
J Immunol; 1992 Jul; 149(1):53-9. PubMed ID: 1607662
[TBL] [Abstract][Full Text] [Related]
13. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination.
Liau LM; Jensen ER; Kremen TJ; Odesa SK; Sykes SN; Soung MC; Miller JF; Bronstein JM
Cancer Res; 2002 Apr; 62(8):2287-93. PubMed ID: 11956085
[TBL] [Abstract][Full Text] [Related]
14. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours.
Pan ZK; Ikonomidis G; Lazenby A; Pardoll D; Paterson Y
Nat Med; 1995 May; 1(5):471-7. PubMed ID: 7585097
[TBL] [Abstract][Full Text] [Related]
15. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy.
Singh R; Paterson Y
Expert Rev Vaccines; 2006 Aug; 5(4):541-52. PubMed ID: 16989634
[TBL] [Abstract][Full Text] [Related]
16. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
17. Listeria-based vaccines for cancer treatment.
Paterson Y; Maciag PC
Curr Opin Mol Ther; 2005 Oct; 7(5):454-60. PubMed ID: 16248280
[TBL] [Abstract][Full Text] [Related]
18. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
19. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector.
Frankel FR; Hegde S; Lieberman J; Paterson Y
J Immunol; 1995 Nov; 155(10):4775-82. PubMed ID: 7594479
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
